Lenvatinib for the treatment of renal cell carcinoma
Sign Up to like & getrecommendations! Published in 2018 at "Expert Opinion on Investigational Drugs"
DOI: 10.1080/13543784.2018.1472235
Abstract: ABSTRACT Introduction: Renal cell carcinoma (RCC) accounts for 2–3% of all solid tumors. Expression of the receptor for the vascular endothelial growth factor (VEGF) is one of the most common features of RCC. Areas covered:… read more here.
Keywords: cell carcinoma; renal cell; lenvatinib treatment;
Lenvatinib treatment for advanced hepatocellular carcinoma: The relationship between efficacy and safety
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz422.042
Abstract: Abstract Background Lenvatinib is a new first-line molecular target drug for hepatocellular carcinoma (HCC) that is available worldwide. We evaluated the efficacy and safety of lenvatinib for unresectable HCC. Methods This study population included thirty-seven… read more here.
Keywords: hepatocellular carcinoma; efficacy safety; lenvatinib treatment;
Lenvatinib treatment for thyroid cancer in COVID era: safety in a patient with lung metastases and SARS-CoV-2 infection
Sign Up to like & getrecommendations! Published in 2021 at "Anti-Cancer Drugs"
DOI: 10.1097/cad.0000000000001097
Abstract: During the coronavirus disease 2019 (COVID-19) pandemic, clinicians are required to manage patient care for pre-existing conditions. Currently, there are no clear indications regarding the management of lenvatinib-treated patients for radioiodine-refractory thyroid cancer and severe… read more here.
Keywords: patient; treatment; lenvatinib treatment; cancer ... See more keywords
Risk Factors for Hepatic Encephalopathy in Hepatocellular Carcinoma After Sorafenib or Lenvatinib Treatment: A Real-World Study
Sign Up to like & getrecommendations! Published in 2022 at "Drug Design, Development and Therapy"
DOI: 10.2147/dddt.s386829
Abstract: Purpose This study aimed to investigate the incidence rate and risk factors for hepatic encephalopathy (HE) among unresectable hepatocellular carcinoma (uHCC) patients with liver cirrhosis who received sorafenib or lenvatinib treatment. Patients and Methods uHCC… read more here.
Keywords: sorafenib lenvatinib; hepatic encephalopathy; lenvatinib treatment; risk factors ... See more keywords
Identification of CT Values That Could Be Predictive of Necrosis (N-CTav) in Hepatocellular Carcinoma after Lenvatinib Treatment
Sign Up to like & getrecommendations! Published in 2022 at "Current Oncology"
DOI: 10.3390/curroncol29050266
Abstract: Purpose: To assess the utility of measurement of the computed tomography (CT) attenuation value (CTav) in predicting tumor necrosis in hepatocellular carcinoma (HCC) patients who achieve a complete response (CR), defined using modified Response Evaluation… read more here.
Keywords: necrosis; n30 ctav; ctav; lenvatinib treatment ... See more keywords
Effect of Lenvatinib treatment on the cell cycle and microRNA profile in hepatocellular carcinoma cells
Sign Up to like & getrecommendations! Published in 2022 at "Biomedical Reports"
DOI: 10.3892/br.2022.1561
Abstract: Lenvatinib is a tyrosine kinase receptor inhibitor used to treat unresectable hepatocellular carcinoma (HCC). In this study, we investigated the antitumor effects of Lenvatinib treatment on HCC cell lines. Proliferation was examined in four HCC… read more here.
Keywords: cell; cell cycle; hepatocellular carcinoma; lenvatinib treatment ... See more keywords